PITTSBURGH, Feb. 14, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today commented on its response to the current shortage of preservative-free Methotrexate Injection.
Mylan CEO Heather Bresch said, "We recognize the critical importance of preservative-free Methotrexate Injection in the treatment of patients with cancer, particularly the pediatric population, and share the concerns of patients and physicians about access to this important product. While Mylan has not had any manufacturing disruption related to its preservative-free Methotrexate Injection, we are aware of, and actively addressing, shortages of this vital drug resulting from manufacturing issues that other suppliers have experienced. Mylan has already ramped up its production in order to try to meet the increased demand and is aggressively working on both the manufacturing and regulatory fronts to expedite the FDA regulatory approvals necessary to further increase capacity."
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.
SOURCE Mylan Inc.